At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Deferasirox and Deferoxaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYPERION)
In Brief
A Phase 2 clinical trial evaluating Deferasirox and Deferoxamine for Cardiac Iron Overload. Completed, enrolled 60 participants across 15 sites in 8 countries.
Detailed Summary
This study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Iron Overload
CountriesCanada, Egypt, Greece, Italy, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartJan 2011
Primary CompletionNov 2013
TodayJul 2026
First PostedDec 6, 2010
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.6 years ago
Interventions
Deferasirox and Deferoxaminedrug